THE DEAL, AT A GLANCE
From the announcementIkena Oncology
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedIkena Oncology raised $100M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersIkena Oncology is positioned around IK-595, an AI MAPK pathway inhibitor for RAS-mutant cancers, with funding directed toward advancing IK-595 to Phase 2 and initiating…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Ikena Oncology · Financing Record
Explore source-linked visual explanations for Ikena Oncology. Unsupported claims are withheld while source review continues.
Record 1668 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →